Literature DB >> 24474573

An association of myeloproliferative neoplasms and obliterative portal venopathy.

Jillian E Mayer1, Thomas D Schiano, Maria Isabel Fiel, Ronald Hoffman, John O Mascarenhas.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24474573     DOI： 10.1007/s10620-013-3018-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

Review 1.  Histopathology of portal hypertension: a practical guideline.

Authors:  T Roskams; A Baptista; L Bianchi; A Burt; F Callea; H Denk; J De Groote; V Desmet; S Hubscher; K Ishak; R MacSween; B Portmann; H Poulson; P Scheuer; L Terracciano; H Thaler
Journal:  Histopathology       Date:  2003-01       Impact factor: 5.087

Review 2.  Non-cirrhotic portal hypertension versus idiopathic portal hypertension.

Authors:  Kunio Okuda
Journal:  J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 4.029

3.  The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Authors:  D Colaizzo; L Amitrano; G L Tiscia; G Scenna; E Grandone; M A Guardascione; V Brancaccio; M Margaglione
Journal:  J Thromb Haemost       Date:  2006-10-20       Impact factor: 5.824

Review 4.  Hepatoportal sclerosis.

Authors:  P Bioulac-Sage; B Le Bail; P H Bernard; C Balabaud
Journal:  Semin Liver Dis       Date:  1995-11       Impact factor: 6.115

5.  Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms.

Authors:  J Hoekstra; E L Bresser; J H Smalberg; M C W Spaander; F W G Leebeek; H L A Janssen
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

6.  Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction.

Authors:  J L Boyer; K P Sen Gupta; S K Biswas; N C Pal; K C Basu Mallick; F L Iber; A K Basu
Journal:  Ann Intern Med       Date:  1967-01       Impact factor: 25.391

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.

Authors:  Selcuk Sozer; Maria Isabel Fiel; Thomas Schiano; Mingjiang Xu; John Mascarenhas; Ronald Hoffman
Journal:  Blood       Date:  2009-03-17       Impact factor: 22.113

9.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 10.  Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

Authors:  Ayalew Tefferi; Michelle Elliott
Journal:  Semin Thromb Hemost       Date:  2007-06       Impact factor: 4.180
  10 in total
  2 in total

Review 1.  Modern management of splenomegaly in patients with myelofibrosis.

Authors:  Douglas Tremblay; Myron Schwartz; Richard Bakst; Rahul Patel; Thomas Schiano; Marina Kremyanskaya; Ronald Hoffman; John Mascarenhas
Journal:  Ann Hematol       Date:  2020-05-17       Impact factor: 3.673

2.  The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib.

Authors:  Douglas Tremblay; Juan Putra; Alexander Vogel; Adam Winters; Ronald Hoffman; Thomas D Schiano; Maria Isabel Fiel; John O Mascarenhas
Journal:  Case Rep Hematol       Date:  2019-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.